FY2025 Earnings Forecast for EHC Issued By Leerink Partnrs

Encompass Health Co. (NYSE:EHC - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Encompass Health in a report released on Wednesday, April 30th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings of $4.95 per share for the year, up from their prior estimate of $4.90. The consensus estimate for Encompass Health's current full-year earnings is $4.80 per share. Leerink Partnrs also issued estimates for Encompass Health's Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.24 EPS and Q4 2026 earnings at $1.31 EPS.

Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.12 EPS.

Several other research firms have also recently weighed in on EHC. StockNews.com cut shares of Encompass Health from a "buy" rating to a "hold" rating in a research report on Saturday. Barclays increased their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. KeyCorp boosted their target price on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. William Blair reissued an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Finally, UBS Group lifted their price target on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Encompass Health has an average rating of "Buy" and an average price target of $120.86.

Encompass Health Price Performance

EHC traded down $0.52 during trading on Friday, hitting $116.12. The company's stock had a trading volume of 759,782 shares, compared to its average volume of 685,605. Encompass Health has a 12 month low of $82.74 and a 12 month high of $117.89. The stock has a market capitalization of $11.69 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The firm's 50 day moving average price is $101.73 and its two-hundred day moving average price is $99.26.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its position in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after purchasing an additional 137 shares during the period. Colonial Trust Co SC acquired a new stake in Encompass Health during the fourth quarter worth about $29,000. Transce3nd LLC acquired a new position in shares of Encompass Health in the 4th quarter valued at approximately $40,000. CBIZ Investment Advisory Services LLC boosted its position in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after acquiring an additional 127 shares in the last quarter. Finally, Tompkins Financial Corp acquired a new position in Encompass Health during the fourth quarter valued at approximately $46,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the sale, the executive vice president now owns 79,710 shares in the company, valued at $9,149,910.90. This represents a 11.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company's stock.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is presently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.